J
John G.F. Cleland
Researcher at National Institutes of Health
Publications - 1276
Citations - 125527
John G.F. Cleland is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Heart failure & Ejection fraction. The author has an hindex of 137, co-authored 1172 publications receiving 110227 citations. Previous affiliations of John G.F. Cleland include Northwestern University & Imperial College London.
Papers
More filters
Journal Article
Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the Cardiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. Commentary
Leslie A. Saxon,John G.F. Cleland,Jean-Claude Daubert,Erland Erdmann,Nick Freemantle,Daniel Gras,Lukas Kappenberger,Luigi Tavazzi +7 more
TL;DR: The CArdiac REsynchronization-Heart Failure (CARF) study as mentioned in this paper randomized patients with left ventricular ejection fraction ≤35, markers of cardiac dyssynchrony, and persistent moderate or severe symptoms of heart failure despite pharmacological therapy, to implantation of a cardiac resynchronization therapy (CRT) device or not.
Journal ArticleDOI
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Theresa McDonagh,Marco Metra,Marianna Adamo,Roy S. Gardner,Andreas Baumbach,Michael Böhm,Haran Burri,Javed Butler,Jelena Čelutkienė,Ovidiu Chioncel,John G.F. Cleland,Andrew J.S. Coats,María G. Crespo-Leiro,Dimitrios Farmakis,Martine Gilard,Stephane Heymans,Arno W. Hoes,Tiny Jaarsma,Ewa A. Jankowska,Mitja Lainscak,Carolyn S.P. Lam,Alexander R. Lyon,John J.V. McMurray,Alexandre Mebazaa,R.H.S Mindham,Claudio Muneretto,Massimo Francesco Piepoli,Susanna Price,Giuseppe M.C. Rosano,Frank Ruschitzka,Anne Kathrine Skibelund +30 more
TL;DR: De Boer et al. as mentioned in this paper reviewed the work of as mentioned in this paper and found that the authors of the paper were concerned with the authorship of the document and not the content of the documents.
Journal ArticleDOI
Rolofylline, an Adenosine A1−Receptor Antagonist, in Acute Heart Failure
Barry M. Massie,Christopher M. O'Connor,Marco Metra,Piotr Ponikowski,John R. Teerlink,Gad Cotter,Beth Davison Weatherley,John G.F. Cleland,Michael M. Givertz,Adriaan A. Voors,Paul DeLucca,George A. Mansoor,Christina M. Salerno,Daniel M. Bloomfield,Howard C. Dittrich +14 more
TL;DR: Rolofylline did not have a favorable effect with respect to the primary clinical composite end point, nor did it improve renal function or 60-day outcomes, and does not show promise in the treatment of acute heart failure with renal dysfunction.
Journal ArticleDOI
Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology
Petar M. Seferovic,Piotr Ponikowski,Stefan D. Anker,Johann Bauersachs,Ovidiu Chioncel,John G.F. Cleland,John G.F. Cleland,Rudolf A. de Boer,Heinz Drexel,Tuvia Ben Gal,Tuvia Ben Gal,Loreena Hill,Tiny Jaarsma,Ewa A. Jankowska,Markus S. Anker,Mitja Lainscak,Basil S. Lewis,Theresa McDonagh,Marco Metra,Davor Miličić,Wilfried Mullens,Massimo F Piepoli,Giuseppe M.C. Rosano,Frank Ruschitzka,Maurizio Volterrani,Adriaan A. Voors,Gerasimos Filippatos,Gerasimos Filippatos,Andrew J.S. Coats +28 more
TL;DR: This expert consensus report is neither a guideline update nor a position statement, but rather a summary and consensus view in the form of consensus recommendations.
Journal ArticleDOI
Expert consensus document: Mitochondrial function as a therapeutic target in heart failure
David Brown,Justin B. Perry,Mitchell E. Allen,Hani N. Sabbah,Hani N. Sabbah,Brian L. Stauffer,Saame Raza Shaikh,John G.F. Cleland,Wilson S. Colucci,Javed Butler,Adriaan A. Voors,Stefan D. Anker,Bertram Pitt,Bertram Pitt,Burkert Pieske,Gerasimos Filippatos,Stephen J. Greene,Mihai Gheorghiade +17 more
TL;DR: In this article, insights into the mechanisms of mitochondrial dysfunction in heart failure are presented, along with an overview of emerging treatments with the potential to improve the function of the failing heart by targeting mitochondria.